POWER THE COURSE OF FIGHTING DISEASES AND SAVING LIVES
Domain expertise, global resource, long-term capital
PORTFOLIO NEWS
2022年8月1日Supported by long-term investors to build leading TPD drug discovery platform and screening...Rona to advance worldwide development of Sanofi siRNA portfolio targeting liver and other...- Advance PRO1184 and PRO1160 into clinical trials - Accelerate multiple programs into...- Funding from long-term investors to build leading delivery platform and scalable drug...CARVYKTI™ marks the first product approved by a health authority for Legend BiotechApproval is...Collaboration Combines Abbisko Therapeutics' Proprietary Drug Discovery Platform with Lilly's...Sperogenix will receive exclusive rights for development and commercialization of vamorolone for...SAN RAFAEL, Calif. and SHANGHAI, Dec. 16, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. ...More Posts
Company
Shanghai
Room 2909-14, 168 Hubin Road, Huangpu District, Shanghai, China.
Hong Kong
Room 606-7, St. George's Building, 2 Ice House Street, Central, Hong Kong
US
2735 Sand Hill Road, Suite 210
Menlo Park, CA 94025
copyright © 2018 Lilly Asia Ventures all rights reserved.
沪公网安备 31010102005458号All Posts
×
LillyAsiaVentures
Lilly Asia Ventures (LAV) is a leading biomedical venture capital firm headquartered in China, with offices in Shanghai, Hong Kong, and Palo Alto.
https://user-assets.sxlcdn.com/images/315509/FnksTvTDur7jpExbqYminmtjWgoM.png?imageMogr2/strip/auto-orient/thumbnail/1200x630>/format/png